Vertex Pharma (VRTX) Granted EU Approval for ORKAMBI to Treat Cystic Fibrosis

November 20, 2015 7:17 AM EST Send to a Friend
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted Marketing Authorization for ORKAMBIĀ® (lumacaftor/ivacaftor), the first ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login